Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02109042 | A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants | PHASE1 | COMPLETED | 15 | — | — | Apr 1, 2014 | Jul 1, 2014 | Jul 16, 2018 | 2 | United States |
The mean maximum observed drug concentration of Blosozumab during 1 dosing interval was reported.
The mean area under the concentration of Blosozumab versus time curve during 1 dosing interval was reported.
| Arm | Type | Description |
|---|---|---|
| Blosozumab | EXPERIMENTAL | Weekly SC injections of blosozumab for 6 weeks. |
| Name | Type | Description |
|---|---|---|
| Blosozumab | DRUG | Administered subcutaneously |
Inclusion Criteria: * Part A: Overtly healthy PMP females * Part B: PMP women who are currently taking oral bisphosphonates * Have a body mass index (BMI) at screening of 19.0 to 35.0 kilogram per square meter (kg/m\^2) Exclusion Criteria: * Show evidence of human immunodeficiency virus (HIV) inf...